Lv5
990 积分 2021-08-26 加入
Developing a Biorelevant Dissolution Method for an Extrudable Core System (ECS) Osmotic Tablet
2天前
已完结
Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry
23天前
已完结
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque Psoriasis
1个月前
已完结
Psoriasis
1个月前
已完结
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
1个月前
已完结
Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects
1个月前
已完结
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
2个月前
已完结
A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
2个月前
已完结
A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
2个月前
已完结
Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs
2个月前
已完结
皖公网安备34019202002308
